A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation
Evidence level: randomised double-blind phase II trial; abstract-only
A 90-patient phase II randomised trial found no difference in FEV1 change between pirfenidone and placebo at 26 weeks in progressive BOS.
As of . Primary source: Publisher record via DOI.
Summary
This investigator-initiated, double-blind, placebo-controlled phase II trial in nine European lung transplant centres randomised 90 adults with bilateral transplants and progressive BOS (477 screened; 48 to pirfenidone 2403 mg per day, 42 to placebo) for 26 weeks. Both groups continued to decline in FEV1 with no significant difference in intention-to-treat, imputed or per-protocol analyses, and graft loss, death and retransplantation were similar. Treatment-related serious adverse events were evenly distributed. The authors conclude pirfenidone did not show superiority and cannot be recommended for BOS. Crossref records online publication on 13 November 2025 and the issue as volume 67 of 2026.
Details
- doi
- 10.1183/13993003.02154-2024
- pmid
- 41232942
- authors
- Perch M, Corris P, Lordan J, Bessa V, Magnusson J, Verleden GM, Vos R, Kneidinger N, Leuckfeld I, Verschuuren E, Gottlieb J
- journal
- European Respiratory Journal
- year
- 2026
- volume
- 67
- issue
- 4
- pages
- 2402154
Sources and links
- Publisher record via DOI (primary)
- PubMed 41232942
Related
Links from this record
- tests treatment in: Bronchiolitis obliterans syndrome (BOS)
- coauthors at: KU Leuven BREATHE (Laboratory of Respiratory Diseases and Thoracic Surgery)
- coauthor: Robin Vos
- coauthor: Geert Verleden
Linked from (derived)
- author affiliation matches this institution (OpenAlex): Newcastle Lung Transplant Programme (Freeman Hospital and Newcastle University)
- author: Geert Verleden
- author: Jesper M. Magnusson
- author: Paul A. Corris
- author: Robin Vos
- evidence: No therapy of proven benefit for established CLAD
Known gaps in this record
- full text not read (abstract only)
- funding statement and grant numbers
- trial registration number (not stated in abstract)
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.